Cingulate CEO updates on ADHD drug NDA resubmission progress

StreetInsider

Cingulate Inc. provided an update on its ADHD drug candidate CTx-1301, detailing efforts to address the FDA's Complete Response Letter and the timeline for resubmitting the New Drug Application. The company is working to complete chemistry, manufacturing, and controls requirements before resubmission, with no assurance on the timeline or approval outcome. The drug uses Cingulate's Precision Timed Release platform and is being evaluated under the FDA's 505(b)(2) pathway.

Read at StreetInsider

All articles from 10 November 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.

Get this news by email

Daily or as a weekly roundup in your inbox. You confirm your address first; every email has an unsubscribe link. For another topic or language, use the subscribe page.

More to read